Matches in SemOpenAlex for { <https://semopenalex.org/work/W2548922080> ?p ?o ?g. }
- W2548922080 abstract "Abstract Immunogenicity of recombinant human acid-alpha glucosidase (rhGAA) in enzyme replacement therapy (ERT) is a safety and efficacy concern in the management of late-onset Pompe disease (LOPD). However, long-term effects of ERT on humoral and cellular responses to rhGAA are still poorly understood. To better understand the impact of immunogenicity of rhGAA on the efficacy of ERT, clinical data and blood samples from LOPD patients undergoing ERT for >4 years (n = 28) or untreated (n = 10) were collected and analyzed. In treated LOPD patients, anti-rhGAA antibodies peaked within the first 1000 days of ERT, while long-term exposure to rhGAA resulted in clearance of antibodies with residual production of non-neutralizing IgG. Analysis of T cell responses to rhGAA showed detectable T cell reactivity only after in vitro restimulation. Upregulation of several cytokines and chemokines was detectable in both treated and untreated LOPD subjects, while IL2 secretion was detectable only in subjects who received ERT. These results indicate that long-term ERT in LOPD patients results in a decrease in antibody titers and residual production of non-inhibitory IgGs. Immune responses to GAA following long-term ERT do not seem to affect efficacy of ERT and are consistent with an immunomodulatory effect possibly mediated by regulatory T cells." @default.
- W2548922080 created "2016-11-11" @default.
- W2548922080 creator A5000175066 @default.
- W2548922080 creator A5000728343 @default.
- W2548922080 creator A5001669795 @default.
- W2548922080 creator A5002690716 @default.
- W2548922080 creator A5003278902 @default.
- W2548922080 creator A5005658456 @default.
- W2548922080 creator A5006189680 @default.
- W2548922080 creator A5007957343 @default.
- W2548922080 creator A5009282279 @default.
- W2548922080 creator A5009848505 @default.
- W2548922080 creator A5011296918 @default.
- W2548922080 creator A5011562601 @default.
- W2548922080 creator A5011918557 @default.
- W2548922080 creator A5014845333 @default.
- W2548922080 creator A5020124452 @default.
- W2548922080 creator A5020873686 @default.
- W2548922080 creator A5023737530 @default.
- W2548922080 creator A5024907189 @default.
- W2548922080 creator A5025693558 @default.
- W2548922080 creator A5026191697 @default.
- W2548922080 creator A5027584008 @default.
- W2548922080 creator A5027640760 @default.
- W2548922080 creator A5028565445 @default.
- W2548922080 creator A5028668736 @default.
- W2548922080 creator A5030912908 @default.
- W2548922080 creator A5032334416 @default.
- W2548922080 creator A5038311277 @default.
- W2548922080 creator A5040923401 @default.
- W2548922080 creator A5041504666 @default.
- W2548922080 creator A5043038167 @default.
- W2548922080 creator A5043773229 @default.
- W2548922080 creator A5044205541 @default.
- W2548922080 creator A5044574847 @default.
- W2548922080 creator A5045345390 @default.
- W2548922080 creator A5045686507 @default.
- W2548922080 creator A5048730442 @default.
- W2548922080 creator A5049298836 @default.
- W2548922080 creator A5050121805 @default.
- W2548922080 creator A5050689401 @default.
- W2548922080 creator A5050704861 @default.
- W2548922080 creator A5051848877 @default.
- W2548922080 creator A5052059190 @default.
- W2548922080 creator A5052422614 @default.
- W2548922080 creator A5052849443 @default.
- W2548922080 creator A5054151429 @default.
- W2548922080 creator A5057324753 @default.
- W2548922080 creator A5059330878 @default.
- W2548922080 creator A5060161748 @default.
- W2548922080 creator A5063223968 @default.
- W2548922080 creator A5063671279 @default.
- W2548922080 creator A5063751762 @default.
- W2548922080 creator A5068521533 @default.
- W2548922080 creator A5070195480 @default.
- W2548922080 creator A5075316221 @default.
- W2548922080 creator A5075655220 @default.
- W2548922080 creator A5076869926 @default.
- W2548922080 creator A5078122354 @default.
- W2548922080 creator A5078659070 @default.
- W2548922080 creator A5079261248 @default.
- W2548922080 creator A5084141736 @default.
- W2548922080 creator A5085182012 @default.
- W2548922080 creator A5086434657 @default.
- W2548922080 creator A5087573583 @default.
- W2548922080 creator A5087961490 @default.
- W2548922080 creator A5088897192 @default.
- W2548922080 creator A5090380092 @default.
- W2548922080 creator A5090431720 @default.
- W2548922080 date "2016-11-04" @default.
- W2548922080 modified "2023-10-18" @default.
- W2548922080 title "Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients" @default.
- W2548922080 cites W1641557591 @default.
- W2548922080 cites W1655559647 @default.
- W2548922080 cites W1719929950 @default.
- W2548922080 cites W1924286396 @default.
- W2548922080 cites W1967259894 @default.
- W2548922080 cites W1970325263 @default.
- W2548922080 cites W1973735640 @default.
- W2548922080 cites W1977004360 @default.
- W2548922080 cites W1983064528 @default.
- W2548922080 cites W1983318494 @default.
- W2548922080 cites W1985662851 @default.
- W2548922080 cites W1986803663 @default.
- W2548922080 cites W1987953408 @default.
- W2548922080 cites W1991782145 @default.
- W2548922080 cites W2000846576 @default.
- W2548922080 cites W2002029791 @default.
- W2548922080 cites W2012027479 @default.
- W2548922080 cites W2012363247 @default.
- W2548922080 cites W2013561924 @default.
- W2548922080 cites W2014246297 @default.
- W2548922080 cites W2020816885 @default.
- W2548922080 cites W2022033278 @default.
- W2548922080 cites W2022749609 @default.
- W2548922080 cites W2029355337 @default.
- W2548922080 cites W2037050042 @default.
- W2548922080 cites W2038188136 @default.
- W2548922080 cites W2040126829 @default.
- W2548922080 cites W2041302559 @default.